Autolus Therapeutics

Autolus is a commercial-stage CAR T-cell therapy company, applying its extensive programming capabilities to develop advanced autologous T-cell therapies that have the potential to deliver life-changing treatments to patients with cancer and autoimmune diseases

In November 2024, Autolus received FDA approval for its lead therapy, AUCATZYL® (obe-cel), for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL), and successfully launched the product commercially in the United States. In April 2025, AUCATZYL® received conditional marketing authorization from the UK Medicines and Healthcare products Regulatory Agency (MHRA), expanding its geographic footprint. This novel CAR T-cell therapy has the potential to be a best-in-class therapy for patients with r/r B-ALL, supported by its very positive safety profile compared to current CD19 CAR T-cell therapies.

Autolus is founded on advanced cell programming technology pioneered by Dr. Martin Pule and was spun-out from University College London in 2014. Chimeric Antigen Receptor (CAR) T-cell therapies have been shown to be effective in some haematological malignancies and may have wide applications as a cancer treatment, with the potential for cure in some patients.

A leader in T-cell programming and manufacturing technology, Autolus works in partnership with physicians and other healthcare providers to extract immune cells from patients, equip them with a receptor that targets the cancer cell, and infuse them back into the patient in order to develop therapies which they believe will offer cancer patients substantial benefits over the existing standard of care.